Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line

Cancer Immunology Immunotherapy

Volumn 42, Issue 5, 1996, Pages 275-279

  Asai, Kiyoshi ^a   Kato, Haruki ^a   Kimura, Shigeru ^a   Mukai, Shigehiko ^a   Kawahito, Yutaka ^a   Sano, Hajime ^a   Kondo, Motoharu ^a   Akaogi, Keiko ^b   Hirose, Kunitaka ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KUREHA CORPORATION   (Japan)

Author keywords

Immunomodulating drug; NO; NO synthase; OK 432; PSK

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; KRESTIN; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL LINE; GENE EXPRESSION; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BASE SEQUENCE; CELL LINE; GENE EXPRESSION REGULATION; INTERFERON TYPE II; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; NITRIC OXIDE SYNTHASE; PICIBANIL; PROTEOGLYCANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029743279     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050282     Document Type: Article

References (36)

1. Akamatsu Y, Fuchimoto S, Orita K (1992) The changing pattern of the splenic lymphocyte subsets in tumor-bearing mice alter oral treatment with OK-432. Jpn J Cancer Res 83:65
2. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A (1986) Identification of a common nucleotide sequence in 3′ untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83:1670
3. Davis LG, Dibner MD, Batty JF (1986) Basic methods in molecular biology. Elsevier, New York
4. Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51:117
5. Gray PW, Goeddel DW (1983) Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci USA 80:5842
6. Hamuro J, Chihara G (1985) Lentinan, a T-cell-oriented immunopotentiator: its experimental and clinical application and possible mechanism of immunomodulation. In: Feniche RL (ed) Immune modulation agents and their mechanisms. Marcel Dekker, New York, pp 409-435
7. Hirose K, Claus OCZ, Oppenheim JJ, Matsushima K (1990) Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 4:475
8. James SL, Glaven J (1990) Macrophage cytotoxicity against schistomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol 143:4208
9. Kariya Y, Okamoto N, Fujimoto T (1991) Lysis of fresh human tumor cells by autologus peripheral blood lymphocyte and tumor infiltratinglymphocytes activated by PSK. Jpn J Cancer Res 82:1044
10. Kato H, Yamamura Y, Inoue M, Tanigawa M, Kimura S, Sugino S, Kondo M (1992) In vitro augmentation of cytotoxicity by N-CWS in peritoneal polymorphonuclear leukocytes (PMNs) induced by PSK, OK 432 or N-CWS. Biotherapy 4:69
11. Kato M, Hirose K, Hakozaki M, Ohno M, Saito Y, Izutani R, Noguchi J, Hori Y, Okumoto S, Kuroda D, Nomura H, Nishimatsu S, Ohoyanagi H (1995) Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 40:52
12. Lorsbach B, Murphy WJ, Lowenstein CJ, Snyder SH, Russel SW (1993) Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. J Biol Chem 268:1908
13. Lowenstein CJ, Snyder SH (1992) Nitric oxide, novel biologic messenger. Cell 70:705
14. Marcinkiewicz J, Chain B (1993) Differential regulation of cytokine production by nitric oxide. Immunology 80:146
15. Marcinkiewicz J, Grabowska A, Chain B (1995) Nitric oxide upregulates the release of inflammatory mediators by mouse macrophages. Eur J Immunol 25:947
16. Mitomi T, Tsuchiya S, Iijima N (1992) Randamized, controlled study on adjuvant immunotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35:123
17. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109
18. Nakazato H, Koike K, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 3431:122
19. Nathan C (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051
20. Ogoshi K (1988) The cooperative study group of PSK for esophageal cancer. Jpn J Cancer Chemother 15:3134
21. Ogoshi K, Miyaji M, Iwata K, Kondoh Y, Tajima T, Mitomi T (1992) Splenectomy, immunosuppressive acidic protein and post-operative immunotherapy in gastric cancer patients with total or proximal gastrectomy: a multivariate analysis. Ann Cancer Res Ther 1:61
22. Okamura K, Suzuki M, Noda K (1986) Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. Cancer 58:865
23. Ozaki S, Okazaki T, Nakao K (1995) Biological response modifiers (BRM) as antigen III. T cell lines specific for BRM kill tumor cells in a BRM specific manner. Cancer Immunol Immunother 40:219
24. Ryoyama K (1992) Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide. Cancer Immunol Immunother 35:7
25. Saito H, Tomioka, H, Sato K (1988) PSK, a polysaccharide from corioulus versicolor, enhances oxygen metabolism of murine peritoneal macrophages and the host resistance to listerial infection. J Gen Microbiol 134:1029
26. Stuehr DJ, Nathan CF (1989) Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169:1543
27. Taylor-Robinson AW, Liew FY, Severn A, Xu D, McSorley SJ, Garside P, Pardon J, Philips RS (1994) Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 24:980
28. Tokunaga T, Taniguchi H, Yoda K, Shimizu M, Sakiyama S (1986) Nucleotide sequence of a full-length cDNA for mouse cytoskeletal beta-actin mRNA. Nucleic Acids Res 14:2829
29. Torisu M, Hayashi Y, Ishimatsu T (1990) Significant prolongation of disease-free period gained by oral PSK administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31: 261
30. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M (1983) New approach to management of malignant ascites with a streptococcal preparation, OK-432: Improvement of host immunity and prolongation of survival. Surgery 93:357
31. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK) Cancer Treat Rev 11:131
32. Watanabe Y, Takashi I (1987) Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Modif 6:169
33. Xie Q-W, Cho H, Calaycay J, Mumford RA, Swiderrek KM, Lee TD, Ding A, Troso T, Nathan C (1992) Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256:225; Cell 70:705
34. Xie Q-W, Cho H, Calaycay J, Mumford RA, Swiderrek KM, Lee TD, Ding A, Troso T, Nathan C (1992) Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256:225; Cell 70:705
35. Yamauchi N, Kuriyama H, Watanabe N, Neda H, Niitsu Y (1989) Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res 49:1671
36. Yang KD, Stone RM, Lee C-S, Chao T-Y, Cheng S-N, Shaio MF (1992) Effects of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 35:277